FAM89A

Across TCGA pan-cancer cohorts, FAM89A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of FAM89A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FAM89A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FAM89A is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where FAM89A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM89A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.122	<.001	11	view →
CCRCC	Male	III,IV	−0.650	<.001	10	view →
LUAD	Male	All	−0.261	<.001	3	view →
OV	All	All	−0.565	.023	2	view →
LSCC	All	III,IV	−0.473	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

FAM89A–HNSC

Open the HNSC breakdown →